162 related articles for article (PubMed ID: 36520636)
41. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
42. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
43. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
44. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
45. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.
Palomba G; Colombino M; Contu A; Massidda B; Baldino G; Pazzola A; Ionta M; Capelli F; Trova V; Sedda T; Sanna G; Tanda F; Budroni M; ; Palmieri G; Cossu A; Contu M; Cuccu A; Farris A; Macciò A; Mameli G; Olmeo N; Ortu S; Petretto E; Pusceddu V; Virdis L
J Transl Med; 2012 Aug; 10():178. PubMed ID: 22931052
[TBL] [Abstract][Full Text] [Related]
47. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
[TBL] [Abstract][Full Text] [Related]
48. Mutation profiling of cancer drivers in Brazilian colorectal cancer.
Dos Santos W; Sobanski T; de Carvalho AC; Evangelista AF; Matsushita M; Berardinelli GN; de Oliveira MA; Reis RM; Guimarães DP
Sci Rep; 2019 Sep; 9(1):13687. PubMed ID: 31548566
[TBL] [Abstract][Full Text] [Related]
49. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
[TBL] [Abstract][Full Text] [Related]
50. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
[TBL] [Abstract][Full Text] [Related]
51. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
[TBL] [Abstract][Full Text] [Related]
52. Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.
Pereira AAL; Fernandes GDS; Braga GTP; Marchetti KR; Mascarenhas CDC; Gumz B; Crosara M; Dib L; Girardi D; Barrichello A; Seidler H
Clin Colorectal Cancer; 2020 Dec; 19(4):e264-e271. PubMed ID: 32741580
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.
Chang DT; Pai RK; Rybicki LA; Dimaio MA; Limaye M; Jayachandran P; Koong AC; Kunz PA; Fisher GA; Ford JM; Welton M; Shelton A; Ma L; Arber DA; Pai RK
Mod Pathol; 2012 Aug; 25(8):1128-39. PubMed ID: 22481281
[TBL] [Abstract][Full Text] [Related]
54. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract][Full Text] [Related]
55. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
Guo F; Gong H; Zhao H; Chen J; Zhang Y; Zhang L; Shi X; Zhang A; Jin H; Zhang J; He Y
Sci Rep; 2018 Apr; 8(1):6076. PubMed ID: 29666387
[TBL] [Abstract][Full Text] [Related]
56. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
57. Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients.
Li X; Yang T; Li CS; Song Y; Lou H; Guan D; Jin L
Theranostics; 2018; 8(6):1678-1689. PubMed ID: 29556349
[TBL] [Abstract][Full Text] [Related]
58. [Incidence of common gene mutations in early-onset colorectal cancer and the association with cancer survival: a meta-analysis].
Zhang RQ; Li SH; Hu TJ; Xu LY; Zhu YS; Li X
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 May; 27(5):495-506. PubMed ID: 38778689
[TBL] [Abstract][Full Text] [Related]
59. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
60. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
